Stratos Wealth Partners LTD. Takes $223,000 Position in Insmed, Inc. $INSM

Key Points

• Stratos Wealth Partners LTD. has acquired a new stake in Insmed, Inc. valued at approximately $223,000, increasing its holdings in the biopharmaceutical sector.
• Insmed received strong support from analysts, with multiple firms raising their target prices and giving it a consensus rating of "Moderate Buy" based on optimistic growth projections.
• Insider transactions revealed significant sales, with key executives selling large quantities of shares, raising questions about confidence in the company's performance amid a 0.3% decline in stock price.

Stratos Wealth Partners LTD. acquired a new stake in Insmed, Inc. (NASDAQ:INSM - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,215 shares of the biopharmaceutical company's stock, valued at approximately $223,000.

Several other hedge funds also recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky acquired a new stake in Insmed in the 1st quarter valued at about $975,000. Chung Wu Investment Group LLC acquired a new stake in Insmed in the 2nd quarter valued at about $173,000. OneDigital Investment Advisors LLC lifted its stake in Insmed by 47.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock valued at $399,000 after purchasing an additional 1,673 shares during the last quarter. Caxton Associates LLP acquired a new stake in Insmed in the 1st quarter valued at about $441,000. Finally, Assenagon Asset Management S.A. lifted its stake in Insmed by 84.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company's stock valued at $7,387,000 after purchasing an additional 33,626 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on INSM. TD Cowen raised their target price on shares of Insmed from $154.00 to $193.00 and gave the company a "buy" rating in a research note on Thursday, October 2nd. Cowen reiterated a "buy" rating on shares of Insmed in a research note on Thursday, October 2nd. Mizuho raised their target price on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. Evercore ISI reiterated an "outperform" rating and issued a $180.00 target price on shares of Insmed in a research note on Wednesday, October 1st. Finally, Truist Financial raised their price objective on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and an average price target of $152.88.

Insider Buying and Selling

In other news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the sale, the insider directly owned 36,461 shares in the company, valued at approximately $5,303,252.45. The trade was a 67.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Lewis sold 6,865 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the transaction, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $30,035,841.60. This represents a 2.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,657 shares of company stock valued at $21,442,198 in the last quarter. Corporate insiders own 3.00% of the company's stock.

Insmed Stock Down 0.3%

NASDAQ INSM opened at $159.66 on Friday. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $168.21. The company has a 50 day moving average of $147.38 and a 200-day moving average of $108.33. The company has a market cap of $33.75 billion, a price-to-earnings ratio of -27.96 and a beta of 1.03.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the previous year, the firm posted ($1.94) earnings per share. The firm's quarterly revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.